Medscape1mon
Beta-Blocker Therapy and Severe Heart Failure: Myth or Reality?
Since most of the clinical trials of -blocking agents have been conducted in patients with heart failure NYHA functional class II/III, until recently there was limited information regarding safety ...
Medscape1mon
Thiazolidinediones and Cardiovascular Disease: Balancing Benefit and Harm
even though persons with NYHA class III or IV heart failure were excluded from the study. Careful screening (based on history and clinical examination) by physicians will not be sufficient to ...
Transcatheter aortic valve replacement in patients with systolic heart failure, aortic stenosis shows limited benefits
Findings from the TAVR UNLOAD study found limited benefits of transcatheter aortic valve replacement (TAVR) in the treatment ...
Transcatheter edge-to-edge repair found non-inferior to surgery in patients with secondary mitral regurgitation
The average age was 70.5 years and 40% were female. The mean LVEF was 43% and heart failure was NYHA class III or IV in 86% ...
thecardiologyadvisor.com4d
Finerenone Reduces Heart Failure Events, Improves Health Status in HFmrEF, HFpEF
Risk for heart failure events is decreased and health status is improved in patients with HFmrEF and HFpEF receiving finerenone.
EurekAlert!13d
Transcatheter aortic valve replacement in patients with systolic heart failure and moderate aortic stenosis shows limited benefits
Findings from the TAVR UNLOAD study found limited benefits of transcatheter aortic valve replacement (TAVR) in the treatment of heart failure (HF) with reduced ejection fraction (HFrEF) and moderate ...